Loading...
Market
Story
FDA Approves Pfizer's ABRYSVO® RSV Vaccine for Adults at Increased Risk on October 22
Oct 23, 2024, 09:05 PM
The U.S. Food and Drug Administration (FDA) has approved Pfizer's RSV vaccine, ABRYSVO®, for adults aged 18 to 59 who are at increased risk for respiratory syncytial virus (RSV) disease. This approval, announced on October 22, aims to prevent lower respiratory tract disease caused by RSV, a common respiratory virus that infects the nose, throat, and lungs. The FDA's expanded approval gives Pfizer a broader label for its RSV vaccine compared to rival shots from GSK and Moderna. Additionally, a large study concluded that the vaccine is 80% effective at preventing hospitalization due to complications from RSV.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 1 million • 25%
1-3 million • 25%
3-5 million • 25%
More than 5 million • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%